A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and chemotherapy as adjuvant therapy in participants with HER2-positive breast cancer.
Epistemonikos ID: dc4c4a9e137668306f39d84e4f3b69feb5120149
First added on: Mar 03, 2026